Form 4: Immuneering Director Laurie Keating Receives Stock Options

Director Laurie Keating was granted 33,350 stock options in Immuneering Corp as part of standard equity compensation.

Summary

• Director Laurie Keating received a grant of 33,350 stock options for Immuneering Corp (IMRX).
• The options have an exercise price of $4.12 per share.
• The grant date is June 11, 2026, with an expiration date of June 11, 2036.
• The options vest in equal monthly installments over a one-year period starting July 11, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation rather than a change in company fundamentals.

Positives

• Aligns director interests with long-term shareholder value through equity-based compensation.

Negatives

• Results in potential future dilution for existing shareholders upon exercise of the options.

Risks

• Market volatility could impact the value of the options relative to the exercise price.
• The value of the equity grant is subject to the future performance of Immuneering Corp stock.

Future Outlook

The options vest over a one-year period, indicating a retention incentive for the director through mid-2027.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard practice in the biotechnology sector to ensure board alignment with corporate milestones and long-term growth objectives.

Comparison to Industry Standards

• The grant of stock options to directors is consistent with standard corporate governance practices for small-cap biotech firms.
• Vesting schedules of one year are relatively aggressive compared to the typical three-to-four-year vesting schedules seen in larger cap companies.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of options to commence on July 11, 2026.

Key Dates

Keywords

Immuneering, IMRX, Form 4, Insider Trading, Stock Options, Director Compensation